Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447637 · ClinicalTrials.gov registry record
PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients
A clinical trial, sponsored by Invitae Corporation.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT05447637: Completed study, sponsored by Invitae Corporation.
NCT05447637 is a clinical trial that has completed, run by Invitae Corporation. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05447637 has completed, sponsored by Invitae Corporation.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
This registry is for men who have prostate cancer and have had multigene panel hereditary testing. The registry will gather data on genetic testing results and how that information may change physician treatment or follow up recommendations. It will also gather data on the patient's experience with genetic testing, through a post-test survey to be completed 60-90days after results have been received and discussed with their provider.
Primary Outcome
Identify the diagnostic yield of pathogenic/likely pathogenic variants in known cancer syndrome genes in patients with prostate cancer, using the Invitae 84 gene multi-cancer panel. These rates will be compared between the two cohorts.
Interventions
- DIAGNOSTIC_TEST Invitae multi-cancer gene panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2022-05-31 |
What the finished NCT05447637 record still lists
NCT05447637 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Invitae multi-cancer gene panel is the first listed.
NCT05447637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05447637 about?
NCT05447637 is a clinical study titled "PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients". This registry is for men who have prostate cancer and have had multigene panel hereditary testing. The registry will gather data on genetic testing results and how that information may change physician treatment or follow up recommendations. It will also gather data on the patient's experience with ...
What is the current status of trial NCT05447637?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2019-11-01. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT05447637?
The interventions under investigation include: Invitae multi-cancer gene panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05447637?
This trial is sponsored by Invitae Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI